Akebia Therapeutics (AKBA) Misses Q3 EPS by 25c

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.42), $0.25 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $60 million versus the consensus estimate of $84.9 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• The free USDA tool that tracks egg prices at $0.62/dozen before your data vendor does
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41